Skip to main content

Select Drug Profiles

ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Clinical Outcomes of Patients with DLBCL, FL, and Richter Transformation Treated with Ibrutinib: A Real-World Experience of Off-Label Ibrutinib Use

ASCO 2017 - Acute Myeloid Leukemia

Differentiation Syndrome Associated with Enasidenib, a Selective Inhibitor of mIDH2

ASCO 2017 - Acute Myeloid Leukemia

Outcomes with Lower-Intensity Therapy in TP53-Mutated AML

ASCO 2017 - Acute Myeloid Leukemia

Enasidenib in Mutant-IDH2 Relapsed or Refractory AML: Results of a Phase 1 Dose-Escalation and Expansion Study

ASCO 2017 - Acute Myeloid Leukemia

Using a Synthetic Control Arm to Establish Early End Points as Indicators of Overall Survival in Acute Myeloid Leukemia

ASCO 2017 - Acute Myeloid Leukemia

Sorafenib plus 5-Azacytidine in Older, Untreated FLT3-ITD–Positive Patients with Acute Myeloid Leukemia

ASCO 2017 - Acute Myeloid Leukemia

Achievement of a Negative MRD State After Hypomethylating Agent Therapy in Older Patients with AML to Reduce Risk of Relapse

ASCO 2017 - Acute Myeloid Leukemia

Assessment of Molecular Response to Gilteritinib in FLT3 Mutation–Positive Relapsed/Refractory Acute Myeloid Leukemia

ASCO 2017 - Acute Myeloid Leukemia

Distinct Patterns of Somatic Mutation Clearance and Association with Clinical Outcome in Patients with AML

ASCO 2017 - Acute Myeloid Leukemia

Prognostic Modeling to Predict Outcomes in Older Patients with AML

Page 89 of 244
Results 881 - 890 of 2434